Company Active LTD

Company profile

Tay Therapeutics Limited

Tay Therapeutics Limited is a UK company with status active founded in 2020 based in Scotland.

CRN
SC651132
Founded
2020
Age
6

Overview

Legal name
TAY THERAPEUTICS LIMITED
Region
Scotland
Registered address
LIFE SCIENCES INNOVATION HUB
5 JAMES LINDSAY PLACE
DUNDEE
SCOTLAND
DD1 5JJ
Insolvency history
No

Latest accounts

Financial period: 1 Feb 2024 to 31 Jan 2025

ABRIDGEDACCOUNTS
Turnover
Unknown
Profit / Loss
Unknown
Employees
12

Company events

Reference milestones and recent Companies House filing stream events.

5 events
31 Oct
2026

Accounts due

Accounts Due

Next accounts due date

06 Aug
2026

Confirmation statement due

Confirmation Due

Next confirmation statement due date

23 Jul
2025

Confirmation statement filed

Confirmation

Last confirmation statement made up date

31 Jan
2025

Accounts filed

Accounts

Last accounts made up date

10 Jan
2020

Incorporated

Inception

Company registered at Companies House

Public funding

2 awards
First funded
2021
Funded years
2021, 2023
Age at first award
1 years

Projects

2023 Collaborative R&D Lead participant

Exploiting read-through compounds as novel anticancer agents with a unique mechanism of action

1 Oct 2023 to 31 Mar 2025

Awarded
£349,786
Total cost £499,694

For cells to produce protein, the DNA that contain our genes, is transcribed into sections of RNA, which are then translated into protein by the ribosome. Translation of proteins is terminated by a specific signal called a stop codon. Many cancers have acquired mutations in their genes which result in premature stop codons in RNA, meaning that the transla...

2021 Collaborative R&D Lead participant

Discovery of a first in class oral anti-inflammatory drug for eczema

1 May 2021 to 28 Feb 2022

Awarded
£77,279
Total cost £110,398

Eczema is the most common inflammatory skin disease, affecting 15-20% of children and up to 10% of adults, associated with substantial morbidity. It is a chronic relapsing condition, with varying frequency and duration of disease flares, in which the symptoms of itching, scratching and infection intensify. There have been few oral small molecule drug appr...

Product types

Collaborative R&D